Gramineae Holdings

Lyell Immunopharma is a clinical-stage biotechnology company dedicated to developing next-generation cell therapies for patients with solid tumors. The company utilizes its proprietary Gen-R and Epi-R technology platforms to reprogram T cells, aiming to overcome the primary barriers to successful adoptive cell therapy: T-cell exhaustion and lack of durable stemness. Lyell's pipeline includes CAR-T and TIL-based programs, such as LYL797 and LYL845, which are currently being evaluated in Phase 1 clinical trials. By focusing on the fundamental biology of T cells, Lyell seeks to create curative therapies for a broad range of cancers that have historically been resistant to immunotherapy.